I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| hepatocyte | 5 studies | 50% ± 25% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| hepatocyte | 5 studies | 50% ± 25% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| liver | 4 studies | 29% ± 9% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| liver | 100% | 67195.28 | 226 / 226 | 98% | 983.83 | 397 / 406 |
| breast | 61% | 594.58 | 280 / 459 | 49% | 46.66 | 551 / 1118 |
| kidney | 69% | 604.19 | 61 / 89 | 30% | 54.76 | 270 / 901 |
| adipose | 92% | 1452.92 | 1102 / 1204 | 0% | 0 | 0 / 0 |
| muscle | 85% | 1220.75 | 679 / 803 | 0% | 0 | 0 / 0 |
| thymus | 62% | 381.68 | 408 / 653 | 7% | 0.31 | 41 / 605 |
| pancreas | 18% | 85.77 | 59 / 328 | 30% | 4.62 | 53 / 178 |
| lung | 30% | 110.41 | 174 / 578 | 16% | 7.66 | 185 / 1155 |
| blood vessel | 45% | 234.62 | 599 / 1335 | 0% | 0 | 0 / 0 |
| bladder | 24% | 55.33 | 5 / 21 | 17% | 5.73 | 88 / 504 |
| uterus | 19% | 59.25 | 32 / 170 | 17% | 6.53 | 80 / 459 |
| stomach | 12% | 37.87 | 43 / 359 | 20% | 5.81 | 56 / 286 |
| heart | 31% | 119.75 | 269 / 861 | 0% | 0 | 0 / 0 |
| skin | 10% | 32.70 | 175 / 1809 | 18% | 2.11 | 83 / 472 |
| adrenal gland | 23% | 28.98 | 59 / 258 | 2% | 0.12 | 4 / 230 |
| intestine | 9% | 36.08 | 85 / 966 | 14% | 6.18 | 73 / 527 |
| lymph node | 0% | 0 | 0 / 0 | 21% | 1.44 | 6 / 29 |
| ovary | 6% | 11.01 | 11 / 180 | 12% | 0.95 | 53 / 430 |
| esophagus | 7% | 18.47 | 95 / 1445 | 10% | 7.11 | 18 / 183 |
| brain | 0% | 0.25 | 5 / 2642 | 13% | 1.29 | 94 / 705 |
| prostate | 10% | 36.63 | 24 / 245 | 3% | 0.13 | 16 / 502 |
| tonsil | 0% | 0 | 0 / 0 | 7% | 0.43 | 3 / 45 |
| peripheral blood | 5% | 16.44 | 46 / 929 | 0% | 0 | 0 / 0 |
| spleen | 2% | 59.41 | 6 / 241 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0031663 | Biological process | lipopolysaccharide-mediated signaling pathway |
| GO_0032722 | Biological process | positive regulation of chemokine production |
| GO_0006953 | Biological process | acute-phase response |
| GO_0002752 | Biological process | cell surface pattern recognition receptor signaling pathway |
| GO_0045087 | Biological process | innate immune response |
| GO_0050829 | Biological process | defense response to Gram-negative bacterium |
| GO_0030593 | Biological process | neutrophil chemotaxis |
| GO_0006968 | Biological process | cellular defense response |
| GO_0043032 | Biological process | positive regulation of macrophage activation |
| GO_0034145 | Biological process | positive regulation of toll-like receptor 4 signaling pathway |
| GO_0050830 | Biological process | defense response to Gram-positive bacterium |
| GO_0071223 | Biological process | cellular response to lipoteichoic acid |
| GO_0032490 | Biological process | detection of molecule of bacterial origin |
| GO_0032757 | Biological process | positive regulation of interleukin-8 production |
| GO_0090023 | Biological process | positive regulation of neutrophil chemotaxis |
| GO_0071222 | Biological process | cellular response to lipopolysaccharide |
| GO_0002281 | Biological process | macrophage activation involved in immune response |
| GO_0002232 | Biological process | leukocyte chemotaxis involved in inflammatory response |
| GO_0008228 | Biological process | opsonization |
| GO_0032720 | Biological process | negative regulation of tumor necrosis factor production |
| GO_0060265 | Biological process | positive regulation of respiratory burst involved in inflammatory response |
| GO_0015920 | Biological process | lipopolysaccharide transport |
| GO_0032760 | Biological process | positive regulation of tumor necrosis factor production |
| GO_0032496 | Biological process | response to lipopolysaccharide |
| GO_0032755 | Biological process | positive regulation of interleukin-6 production |
| GO_0005615 | Cellular component | extracellular space |
| GO_0005576 | Cellular component | extracellular region |
| GO_0016020 | Cellular component | membrane |
| GO_0070062 | Cellular component | extracellular exosome |
| GO_0009986 | Cellular component | cell surface |
| GO_0015026 | Molecular function | coreceptor activity |
| GO_0005102 | Molecular function | signaling receptor binding |
| GO_0071723 | Molecular function | lipopeptide binding |
| GO_0001530 | Molecular function | lipopolysaccharide binding |
| GO_0005515 | Molecular function | protein binding |
| GO_0070891 | Molecular function | lipoteichoic acid binding |
| Gene name | LBP |
| Protein name | Lipopolysaccharide-binding protein (LBP) |
| Synonyms | |
| Description | FUNCTION: Plays a role in the innate immune response. Binds to the lipid A moiety of bacterial lipopolysaccharides (LPS), a glycolipid present in the outer membrane of all Gram-negative bacteria . Acts as an affinity enhancer for CD14, facilitating its association with LPS. Promotes the release of cytokines in response to bacterial lipopolysaccharide . . FUNCTION: Plays a role in the innate immune response. Binds to the lipid A moiety of bacterial lipopolysaccharides (LPS), a glycolipid present in the outer membrane of all Gram-negative bacteria. Acts as an affinity enhancer for CD14, facilitating its association with LPS. Promotes the release of cytokines in response to bacterial lipopolysaccharide. . |
| Accessions | P18428 ENST00000217407.3 Q8TCF0 |
